I agree in part but I wouldn't call a new drug with only phase II trials exactly a safe bet. This is biotech and it's always risky. We have a company that has struggled in the past and has not proven itself. We have a drug with established competition. Now we have a pipeline that has become somewhat unstable. This has been known so I don't think we have many shareholders jumping in at this point.
However I hope we have a lot of people watching this stock for sales numbers. You can't beat increasing sales and increasing markets. We have the increasing markets part done. I'm hoping we see something that CLEARLY shows impressive sales. Then the PPS will move up.
I know some saw it as a Femprox play but some also saw it as a Vitaros play. I don't think big money will invest in this until they see sales. The reviews sound good so I'm hoping it all works out by the end of the year. I hope to see you all there.
News 
Market Data 
Discover 
